Project Grant R01CA288651
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$801K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $577,680.00 to The Regents of the University of Colorado to conduct research aimed at "TARGETING EHMT1/2 TO OVERCOME THERAPY-RESISTANT OVARIAN CANCER". The research, to be performed at the University of Colorado in Boulder, CO, seeks to develop innovative medical solutions to transform healthcare for military service members, veterans, and the...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...
This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a short RNA therapeutic to treat ovarian cancer at Nuago Therapeutics Inc. in Chicago, IL. The award will fund research to create a novel, targeted therapy that aims to induce DNA damage in ovarian cancer cells. This project, running from June 2025 through May 2026, seeks to advance a potential new treatment approach that could improve outcomes for...
This federal Project Grant award of $470,567.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) aims to identify molecular features that influence response or resistance to PARP-inhibitor treatment in metastatic breast cancer patients without germline BRCA1/2 mutations. The award will fund analysis of pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA samples from 108 patients enrolled in...
This federal Project Grant award of $412,429 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate novel approaches to overcome drug resistance in high-grade serous ovarian cancer (HGSOC). The award aims to demonstrate that combining the drug clofarabine with either a PARP inhibitor or an ATR inhibitor can sensitize CCNE1-driven tumors to these therapies by inducing replication stress through nuclear translocation of the protein cathepsin...
This $437,432 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at developing strategies to eradicate leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) patients who have relapsed after initial treatment with venetoclax and azacitidine. The key goals of the project are to: 1) characterize and target venetoclax/azacitidine-resistant LICs, 2) evaluate the use of lower-dose mitoxantrone in combination...
This federal Project Grant award of $1,598,801.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel for the treatment of recurrent platinum-resistant ovarian cancer. The study is being conducted by the Dana-Farber Cancer Institute, Inc., a renowned non-profit cancer research and treatment center in Boston, Massachusetts. The award period runs from July 1, 2025...
The University of Colorado-Denver has been awarded a $1,130,984 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "DEFINING AND TARGETING CHROMOBOX2 (CBX2)-MEDIATED CHEMORESISTANCE IN HIGH GRADE SEROUS CARCINOMA". The grant will support the university's research efforts to investigate novel approaches for overcoming chemoresistance in high-grade serous carcinoma, a form of ovarian cancer, over a...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $204,474 to The Regents of the University of Colorado to conduct research aimed at defining the relationship between cell quiescence and senescence. The project will use advanced microscopy techniques and RNA sequencing to study the molecular mechanisms that mediate the transition from a reversible quiescent state to permanent cell cycle arrest, or senescence. The research...